Chimerix price target raised to $63 from $44 at Piper Jaffray Piper Jaffray analyst Joshua Schimmer raised his price target for Chimerix to $63 on expectations the company will gain approval next year for three antiviral indications simultaneously. All evidence points to a high probability of success for the Phase 3 study of brincidofovir for allogeneic hematopoetic stem cell transplant, Schimmer tells investors in a research note. Shares have rallied as key data readouts near for brincidofovir, he notes. The analyst keeps an Overweight rating on Chimerix.
Chimerix completes enrollment for Brincidofovir Phase 3 AdVise trial Chimerix announced completion of enrollment of the targeted 200 patients in the Phase 3 AdVise trial evaluating brincidofovir for the treatment of adenovirus infection in immunocompromised patients. Adenovirus is a common virus that leads to upper respiratory or gastrointestinal infections in individuals with a healthy immune system, but it can be rapidly fatal in individuals with a weakened immune system, particularly those who have recently undergone a hematopoietic cell transplant, or bone marrow transplant. There is no approved antiviral treatment for adenovirus infection.